This report comes with 10% free customization, enabling you to add data that meets your specific business needs.
The increasing incidence of genetic disorders and cancer in Saudi Arabia has heightened the demand for advanced diagnostic tools. NGS offers comprehensive genomic insights, facilitating early detection and personalized treatment strategies. According to GLOBOCAN, cancer incidence in Saudi Arabia is projected to reach 39,900 cases by 2030, up from 28,113 cases in 2022.
Additionally, institutions such as King Faisal Specialist Hospital & Research Centre (KFSHRC) and KAUST (King Abdullah University of Science and Technology) are at the forefront of genomic sequencing research. Saudi Arabia is funding precision medicine research projects, increasing the adoption of NGS in clinical applications. Furthermore, technological advancements in NGS platforms, bioinformatics, and AI-powered analytics are further accelerating the market. Companies such as Illumina, Thermo Fisher Scientific, and Oxford Nanopore are expanding their presence in Saudi Arabia, providing high-throughput sequencing solutions at reduced costs.
In addition, the adoption of personalized medicine in Saudi Arabia is another critical growth factor for the NGS market. NGS-driven targeted therapies and pharmacogenomics are increasingly being used to guide treatment decisions, especially in oncology. Cancer mutation profiling through NGS allows for precise drug selection and immunotherapy, while pharmacogenomic testing helps reduce adverse drug reactions and improves treatment outcomes.
However, the high cost of NGS technology and implementation is anticipated to pose a significant challenge for market growth. NGS technology remains expensive, making it less accessible for many healthcare institutions and research centers in Saudi Arabia. The cost of whole genome sequencing (WGS) can range from $500 to $1,000 per sample, while targeted sequencing panels cost between $200 and $500. Since Saudi Arabia aims to scale genomic research through national initiatives like the Saudi Human Genome Project (SHGP), the demand for local data processing capabilities is increasing. However, setting up dedicated genomic data centers requires significant investment in cybersecurity, data privacy compliance, and computing power.
Key players in the Saudi Arabia NGS market are actively advancing the field through various initiatives and collaborations. For instance, in October 2024, Illumina introduced the MiSeq i100 Series sequencing systems, designed to enhance NGS capabilities for laboratories by offering rapid turnaround times and user-friendly interfaces.
Key players in the market are Thermo Fisher Scientific Inc., Pacific Biosciences of California, Inc., Oxford Nanopore Technologies plc, Agilent Technologies, Inc., Qiagen N.V., Pillar Biosciences, Singular Genomics Systems, Inc., Danaher Corporation, F. Hoffmann-La Roche Ltd, Twist Bioscience Corporation, Revvity, Inc., Qiagen, and PerkinElmer Inc., etc.
Market Segmentation:
Segmentation 1: by Product
- Sample Preparation
- Sequencing
Segmentation 2: by Technology
- Sequencing by Synthesis
- Ion Torrent Semiconductor Sequencing
- Single-Molecule Real-Time (SMRT) Sequencing
- Nanopore Sequencing Technology
- Other Technologies
Segmentation 3: by Sequencing
- Whole-genome sequencing (WGS)
- Whole-Exome Sequencing (WES)
- Targeted Sequencing
- Others
Segmentation 4: by Application
- Clinical Diagnostics
- Oncology
- Rare Diseases
- Infectious Diseases
- Others
- Research & Academic
Segmentation 5: by End Users
- Academic and Research Institutes
- Clinical Laboratories
- Pharmaceutical and Biotechnology Companies
This product will be updated with the latest data at the time of order. Consequently, dispatch time for this product will be 7-10 business days.
Table of Contents
Companies Mentioned
- Illumina, Inc.
- Thermo Fisher Scientific Inc.
- Pacific Biosciences of California, Inc.
- Oxford Nanopore Technologies plc.
- Agilent Technologies, Inc.
- Qiagen N.V.
- Pillar Biosciences
- Singular Genomics Systems, Inc.
- DANAHER CORPORATION
- F. Hoffmann-La Roche Ltd
- Twist Bioscience Corporation
- Revvity, Inc.
- Qiagen
- PerkinElmer Inc.